265 related articles for article (PubMed ID: 30767446)
1. [Chapter 2. Clinical trials of advanced therapy medicinal products: which future for the European regulation].
Mahalatchimy A; De Grove-Valdeyron N
J Int Bioethique Ethique Sci; 2018 Jul; 29(2):35-51. PubMed ID: 30767446
[TBL] [Abstract][Full Text] [Related]
2. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N
Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215
[TBL] [Abstract][Full Text] [Related]
3. Regulation of Clinical Trials with Advanced Therapy Medicinal Products in Germany.
Renner M; Anliker B; Sanzenbacher R; Schuele S
Adv Exp Med Biol; 2015; 871():87-101. PubMed ID: 26374214
[TBL] [Abstract][Full Text] [Related]
4. Hospital Exemption for Advanced Therapy Medicinal Products: Issue in Application in the European Union Member States.
Ivaskiene T; Mauricas M; Ivaska J
Curr Stem Cell Res Ther; 2017; 12(1):45-51. PubMed ID: 27412678
[TBL] [Abstract][Full Text] [Related]
5. [Advanced therapy: from European regulatory framework to national regulatory framework].
Lucas-Samuel S
Transfus Clin Biol; 2013 May; 20(2):221-4. PubMed ID: 23517820
[TBL] [Abstract][Full Text] [Related]
6. Overview of the Regulatory Oversight Implemented by the French Regulatory Authorities for the Clinical Investigation of Gene Therapy and Cell Therapy Products.
Lucas-Samuel S; Ferry N; Trouvin JH
Adv Exp Med Biol; 2015; 871():73-85. PubMed ID: 26374213
[TBL] [Abstract][Full Text] [Related]
7. Regulation of Cell and Gene Therapy Medicinal Products in Taiwan.
Lin YC; Wang PY; Tsai SC; Lin CL; Tai HY; Lo CF; Wu SI; Chiang YM; Liu LL
Adv Exp Med Biol; 2015; 871():181-94. PubMed ID: 26374219
[TBL] [Abstract][Full Text] [Related]
8. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
Kroes BH
J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
[TBL] [Abstract][Full Text] [Related]
9. Creating conditions for the success of the French industrial advanced therapy sector.
Lirsac PN; Blin O; Magalon J; ; Angot P; de Barbeyrac E; Bilbault P; Bourg E; Damour O; Faure P; Ferry N; Garbil B; Larghero J; Nguon M; Pattou F; Thumelin S; Yates F
Therapie; 2015; 70(1):69-94. PubMed ID: 25747840
[TBL] [Abstract][Full Text] [Related]
10. Advanced therapy medicinal product manufacturing under the hospital exemption and other exemption pathways in seven European Union countries.
Coppens DGM; Hoekman J; De Bruin ML; Slaper-Cortenbach ICM; Leufkens HGM; Meij P; Gardarsdottir H
Cytotherapy; 2020 Oct; 22(10):592-600. PubMed ID: 32563611
[TBL] [Abstract][Full Text] [Related]
11. REIMBURSEMENT OF CELL-BASED REGENERATIVE THERAPY IN THE UK AND FRANCE.
Mahalatchimy A
Med Law Rev; 2016; 24(2):234-58. PubMed ID: 27083495
[TBL] [Abstract][Full Text] [Related]
12. Requirements for Clinical Trials with Gene Therapy and Transplant Products in Switzerland.
Marti A
Adv Exp Med Biol; 2015; 871():131-45. PubMed ID: 26374216
[TBL] [Abstract][Full Text] [Related]
13. Clinical Trials on Advanced Therapy Investigational Medicinal Products in Spain (2004-2022): Experience and Challenges for the Future.
Estévez Álamo J; Timón M; Sánchez Afán de Rivera I; Iriarte Torres B; Serrano Castro MA
Adv Exp Med Biol; 2023; 1430():23-39. PubMed ID: 37526840
[TBL] [Abstract][Full Text] [Related]
14. The European hospital exemption clause-new option for gene therapy?
Buchholz CJ; Sanzenbacher R; Schüle S
Hum Gene Ther; 2012 Jan; 23(1):7-12. PubMed ID: 22247961
[TBL] [Abstract][Full Text] [Related]
15. Patient access to and ethical considerations of the application of the European Union hospital exemption rule for advanced therapy medicinal products.
Cuende N; Ciccocioppo R; Forte M; Galipeau J; Ikonomou L; Levine BL; Srivastava A; Zettler PJ
Cytotherapy; 2022 Jul; 24(7):686-690. PubMed ID: 35545453
[TBL] [Abstract][Full Text] [Related]
16. [Academic cell therapy facilities are challenged by European regulation on advanced therapy medicinal products].
Chabannon C; Sabatier F; Rial-Sebbag E; Calmels B; Veran J; Magalon G; Lemarie C; Mahalatchimy A
Med Sci (Paris); 2014 May; 30(5):576-83. PubMed ID: 24939546
[TBL] [Abstract][Full Text] [Related]
17. Regulatory Oversight of Cell- and Tissue-Based Therapeutic Products and Gene Therapy Products in Singapore.
Goh CW; Kellathur SN; Ong LL; Wu X
Adv Exp Med Biol; 2015; 871():195-212. PubMed ID: 26374220
[TBL] [Abstract][Full Text] [Related]
18. Update on Regulation of Regenerative Medicine in Taiwan.
Chao WY; Chang YT; Tsai YT; Huang MC; Lin YC; Wu MM; Chi JF; Lin CL; Cheng HF; Wu SM
Adv Exp Med Biol; 2023; 1430():211-219. PubMed ID: 37526850
[TBL] [Abstract][Full Text] [Related]
19. Regulatory Oversight of Gene Therapy and Cell Therapy Products in Korea.
Choi M; Han E; Lee S; Kim T; Shin W
Adv Exp Med Biol; 2015; 871():163-79. PubMed ID: 26374218
[TBL] [Abstract][Full Text] [Related]
20. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
Pflieger M; Bertram D
Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
